Navigation Links
Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines
Date:10/11/2007

- Potential misuse of these infant medicines, not product safety, is

driving the voluntary withdrawal - This withdrawal does not affect cough and cold medicines for children age

2 and older - Further evaluation of these oral cough and cold medicines for infants and children will occur at the October 18 and 19 FDA advisory committee meeting

WASHINGTON, Oct. 11 /PRNewswire/ -- The Consumer Healthcare Products Association (CHPA) on behalf of the leading makers of over-the-counter cough and cold medicines today announced voluntary market withdrawals of oral cough and cold medicines that refer to "infants." The voluntary withdrawal affects only these "infant" oral medicines, not those intended and labeled for use in children age two and older.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071011/NYTH021 )

"It's important to point out that these medicines are safe and effective when used as directed, and most parents are using them appropriately," said Linda A. Suydam, D.P.A, president of CHPA. "The reason the makers of over-the- counter, oral cough and cold medicines for infants are voluntarily withdrawing these medicines is that there have been rare patterns of misuse leading to overdose recently identified, particularly in infants, and safety is our top priority."

The branded cough and cold medicines that are being voluntarily withdrawn are:

-- Dimetapp(R) Decongestant Plus Cough Infant Drops

-- Dimetapp(R) Decongestant Infant Drops

-- Little Colds(R) Decongestant Plus Cough

-- Little Colds(R) Multi-Symptom Cold Formula

-- PEDIACARE(R) Infant Drops Decongestant (containing pseudoephedrine)

-- PEDIACARE(R) Infant Drops Decongestant & Cough (containing

pseudoephedrine)

-- PEDIACARE(R) Infant Dropper Decongestant (containing phenylephrine)

-- PEDIACARE(R) Infant Dropper Long-Acting Cough

-- PEDIACARE(R) Infant Dropper Decongestant & Cough (containing

phenylephrine)

-- Robitussin(R) Infant Cough DM Drops

-- Triaminic(R) Infant & Toddler Thin Strips(R) Decongestant

-- Triaminic(R) Infant & Toddler Thin Strips(R) Decongestant Plus Cough

-- TYLENOL(R) Concentrated Infants' Drops Plus Cold

-- TYLENOL(R) Concentrated Infants' Drops Plus Cold & Cough

This voluntary withdrawal does not affect medicines intended for children age two and older. CHPA and its member companies have put forth recommendations to the U.S. Food and Drug Administration (FDA) to strengthen the labels on all oral OTC children's cough and cold medicines from "ask a doctor" before using to "do not use" in children under two years.

CHPA made these recommendations to the FDA in preparation for a joint FDA advisory committee meeting on October 18 and 19. These recommendations, as well as several additional recommendations, including those proposed by FDA review staff, will be explored further at this meeting.

"These medicines are -and always have been- safe at recommended doses," Suydam said. "These voluntary actions are being taken out of an abundance of caution. The vast majority of parents and caregivers safely use these medicines to help relieve their children's symptoms. But as with all medicines, it's important that parents read over-the-counter medicine labels carefully, use these medicines only as directed, and store them safely out of the reach of children."

CHPA will be launching a major, multi-year national campaign to educate parents and healthcare providers about the safe use of over-the-counter medicines in children, partnering with major physician, nurse, and pharmacist organizations.

More information about the voluntary withdrawal can be found at http://www.OTCSafety.org.

CHPA is the 126-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplement products.

Contacts: Elizabeth Funderburk and Virginia Cox

202.429.9260

E. Funderburk cell: 202.256.5677


'/>"/>
SOURCE The Consumer Healthcare Products Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers identify the early makers of Neonatal Sepsis
2. Epilepsy Patients Could Benefit From Pacemakers
3. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
4. Stem Cells Could Replace Electronic Pacemakers
5. Lawmakers alerted on new tobacco control policies by research team
6. Chocolate makers to be health wise and urge consumers to be too!
7. Drug Makers Banned From Providing Gifts To Doctors
8. Lawsuit Against Sunscreen Makers For False Claims of Protection Against Skin Cancer
9. Sensing The Health Hazard MP3 Makers Tone Down The Volume
10. Reliability of Pacemakers and Defibrillators to be Improved
11. Food Makers Pressurized to Reduce Salt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 16, 2017 , ... Date aired: January 9, 2017 , ... Kleyne, America’s leading water educator, researcher and advocate welcomed health activist, author, science ... Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ...
(Date:1/16/2017)... , ... January 16, 2017 , ... One thing common ... to treat, but to test for, as well. The money spent screening for and ... Doctors in the U.S. screen patients for cancer more than in any other country ...
(Date:1/16/2017)... WA (PRWEB) , ... January 16, 2017 , ... NexTec ... 2016, a group of 100 organizations honored for their accomplishments in the field of ... such growth, industry leadership and recognition, and innovation. Selection is not based on revenue ...
(Date:1/15/2017)... , ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release ... are also new avenues for purchase. , The 2017 edition has wide jaws that ... for the older boomers as well as diabetics. This handle is reinforced for extra strength ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted ... managing the award process. Results were announced the magazine’s January 2017 issue ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... January 13, 2017 Constant research ongoing ... will collectively contribute to the demand for western blotting technique. ... value of US$ 551.0 Mn by 2016 end. Developing economies ... most lucrative markets for western blotting, whereas North ... ...
(Date:1/13/2017)... MURRIETA, Calif. , Jan. 13, 2017  Alfalfa, cattle, ... COPAN Diagnostic,s new environmental sampling film , which emphasizes the ... video, released today, highlights how COPAN,s ... product that simplifies the surface sampling process in the wake ... . In addition, COPAN is expanding ...
(Date:1/13/2017)... -- This morning, Stock-Callers.com draws attention to ... at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... to develop technologies and products that combat debilitating and ... use less and cleaner energy, and provide safer, cleaner ...
Breaking Medicine Technology: